In conclusion, our results show high concordance between tumor tissue and ctDNA mutation status and suggest that serum samples from advanced breast cancer patients and ddPCR may be used for PIK3CA mutation status assessment to complement imaging techniques as a tool for monitoring treatment response. Here, PIK3CA is linked to neoplasm.